Hypoparathyroidism – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Hypoparathyroidism Market Outlook

Thelansis’s “Hypoparathyroidism Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hypoparathyroidism treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hypoparathyroidism Overview

Hypoparathyroidism manifests as a condition typified by decreased serum calcium levels and elevated serum phosphorus levels attributable to deficient secretion or activity of parathyroid hormone (PTH). Etiologically, hypoparathyroidism can arise as a component of either pluriglandular autoimmune disorders or complex congenital anomalies, exemplified by autosomal dominant DiGeorge syndrome or hypoparathyroidism, deafness, and renal dysplasia (HDR) syndromes. Moreover, isolated or idiopathic hypoparathyroidism denotes cases devoid of accompanying systemic abnormalities. The etiology of hypoparathyroidism is multifactorial and encompasses:

1. Developmental anomalies of the parathyroid glands
2. Iatrogenic injuries to the parathyroid glands
3. Diminished parathyroid gland function due to dysregulated regulatory mechanisms
4. Impaired responsiveness to PTH

Manifestations of hypoparathyroidism arise from the consequences of reduced serum calcium levels on various organ systems, and their severity correlates with the extent and rapidity of hypocalcemia. Persistent hypoparathyroidism poses a significant risk following central neck surgeries, particularly bilateral procedures or simultaneous thyroidectomy and parathyroidectomy, as well as in cases of autoimmune thyroid disorders, central neck dissections, substernal goiters, procedures performed by low-volume surgeons, and prior gastric bypass surgeries. The FDA has sanctioned Natpara (rhPTH(1-84)) for managing hypoparathyroidism in adults. Natpara represents a novel once-daily subcutaneously injectable recombinant PTH formulation, the sole prescription medication approved by the FDA for controlling hypocalcemia when co-administered with calcium and vitamin D in adult hypoparathyroidism patients.

• The incidence of hypoparathyroidism in the United States is estimated to range from 24 to 37 cases per 100,000 person-years, affecting an estimated 60,000 to 80,000 individuals.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: